Abstract: A glucagon analogue containing a lactam bridge between a Lysine introduced at position 13 and a Glutamic Acid introduced at position 17, optionally including C-terminal extensions and optionally including a second side-chain/side-chain staple beginning at or C-terminal to residue 20. The second staple may also be an (i, i+4) lactam bridge, an (i, i+3) disulfide bridge between D-Cysteine and L-Cysteine or an (i, i+7) disulfide bridge between L-Cysteine and L-Cysteine. A fusion protein containing an N-terminal lactam-stabilized glucagon analogue as above and a C-terminal single-chain insulin (SCI) analogue wherein the C domain of the SCI contains 4-11 residues is also disclosed herein. A method of treating a patient with diabetes mellitus comprises the subcutaneous, intraperitoneal, or oral administration of a physiologically effective amount of the glucagon analogue or glucagon-SCI fusion protein is also provided.

Abstract: A two-chain insulin analogue is provided containing (a) a B chain modified by a C-terminal diol element such that one hydroxyl group substitutes for the C-terminal carboxylate function in combination with (b) a glucose-binding element attached to the A chain at or near its N terminus. Compositions comprising such insulin analogs are used in methods of treating a patient with diabetes mellitus.

Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Abstract: The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.

Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Abstract: The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can be used therapeutically or prophylactically against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Abstract: The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise: (a) a PTH/PTHrP modulating domain; and (b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain or through a sidechain at any residue from residue 14 through the C-terminal residue. The vehicle and the PTH/PTHrP modulating domain may be linked through the N- or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is PEG. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein.